Zenas Biopharma Inc [ZBIO] stock is trading at $31.25, up 4.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZBIO shares have gain 30.78% over the last week, with a monthly amount glided 49.16%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zenas Biopharma Inc [NASDAQ: ZBIO] stock has seen the most recent analyst activity on March 20, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $35. Previously, Wolfe Research started tracking the stock with Outperform rating on February 04, 2025, and set its price target to $19. On December 16, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $30 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $34 on November 05, 2024. Morgan Stanley initiated its recommendation with an Overweight and recommended $40 as its price target on October 08, 2024. Jefferies started tracking with a Buy rating for this stock on October 08, 2024, and assigned it a price target of $35. In a note dated October 08, 2024, Guggenheim initiated a Buy rating and provided a target price of $45 on this stock.
Zenas Biopharma Inc [ZBIO] stock has fluctuated between $5.83 and $34.33 over the past year. Currently, Wall Street analysts expect the stock to reach $43.33 within the next 12 months. Zenas Biopharma Inc [NASDAQ: ZBIO] shares were valued at $31.25 at the most recent close of the market. An investor can expect a potential return of 38.66% based on the average ZBIO price forecast.
Analyzing the ZBIO fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -12.61%, Pretax Profit Margin comes in at -11.78%, and Net Profit Margin reading is -11.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.59 and Total Capital is -0.79. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.12 points at the first support level, and at 28.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.15, and for the 2nd resistance point, it is at 33.04.
Ratios To Look Out For
For context, Zenas Biopharma Inc’s Current Ratio is 5.23. Further, the Quick Ratio stands at 5.23, while the Cash Ratio is 0.83. Considering the valuation of this stock, the price to sales ratio is 87.73, the price to book ratio is 5.49.
Transactions by insiders
Recent insider trading involved Nunn Jason Raleigh, Director, that happened on Oct 09 ’25 when 63158.0 shares were purchased. 10% Owner, SR ONE CAPITAL MANAGEMENT, LLC completed a deal on Oct 09 ’25 to buy 0.13 million shares. Meanwhile, Director ENRIGHT PATRICK G bought 0.11 million shares on Oct 09 ’25.
